Browse all Peptides & GLP-1 education Retatrutide is an investigational triple agonist that engages the GLP-1, GIP, and glucagon receptors
This research explores how GLP-1 relates to spontaneous energy intake
In studies, both forms of semaglutide (Wegovy) show similar weight loss results, particularly among patients who are good at taking it as prescribed
Understanding your genetic predisposition to lipid dysfunction and medication response helps PlexusDx providers personalize your semaglutide dose and formulation
References and Clinical Sources ClinicalTrials.gov
The FDA has approved several GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)